Kuo, . Tzu-Chieh
Chao, . Hung-Yu
Chang, . Chuen
Hsueh, . Chih-Lang
Lin, . Kun-Chun
Chiang, . Wen-Yu
Chuang, . Yung-Chih
Chen, . Jen-Der
To investigate the influence of serum anti-thyroglobulin antibody (TgAb) on the prognosis in papillary thyroid cancer (PTC) patients. In this retrospective study, the participants were enrolled from 1206 PTC patients (927 women, 279 men, mean age, 42.2 years) with T2 and higher, or N1 or M1 classifications in tumor–node–metastasis staging after total thyroidectomy. We recorded the final serum TgAb data (on thyroxin therapy) at the end of follow-up in 2012. Patients were classified as negative TgAb or positive TgAb groups on the basis of their serum TgAb levels (< 70 IU/mL or ≥ 70 IU/mL). Among the 1206 patients, after mean follow-up for 11.6 ± 6.1 years (range, 2.0–29.2 years), there were 75 with positive TgAb and 1131 with negative TgAb. Patient categorization depending on the follow-up time (2–5 years after surgery, 5–10 years after surgery, and 10–30 years after surgery) was performed. In comparison to traditional risk factors, such as age, tumor size, and sex, which were important prognostic factors for cancer recurrence and mortality in PTC patients, there was no significant difference in the prognosis between positive TgAb patients and negative TgAb patients by the multivariate analyses (cancer recurrence, p = 0.164, p = 0.112, p = 0.202, respectively, cancer mortality, p = 0.181, p = 0.646, p = 0.656, respectively) based on the different follow-up times. Positive serum TgAb was not a risk factor, and was not associated with the prognosis of PTC patients.
Diff selection: Mark the radio boxes of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.
Published on 26/05/17Submitted on 26/05/17
Views 10Recommendations 0
Are you one of the authors of this document?